942935-99-1

Basic information

• Product Name: 5-(azidomethyl)-3-phenylisoxazole
• Synonyms: 5-(azidomethyl)-3-phenylisoxazole
• CAS NO: 942935-99-1
• Molecular Weight: 200.2
• Mol File: 942935-99-1.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 5-(azidomethyl)-3-phenylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(azidomethyl)-3-phenylisoxazole(942935-99-1)
• EPA Substance Registry System: 5-(azidomethyl)-3-phenylisoxazole(942935-99-1)

Safety Data

• Hazardous Substances Data: 942935-99-1(Hazardous Substances Data)

Upstream product

• 2039-50-1 5-bromomethyl-3-phenyl-isoxazole 
• 698-16-8 benzohydroximoyl chloride 
• 932-90-1 syn-benzaldehyde oxime 
• 1011-37-6 3-phenyl-5-chloromethyl-1,2,4-oxadiazole 
• 932-90-1 Benzaldoxime 
• 100-52-7 benzaldehyde 
• 90924-12-2 3-phenyl-5-hydroxymethylisoxazole 

Downstream Products

• 54408-35-4 1-(3-phenyl-1,2-oxazol-5-yl)methanamine 
• 339016-92-1 4-chloro-N-((3-phenylisoxazol-5-yl)methyl)benzenesulfonamide 

Relevant articles and documents

Quinazoline derivatives preparation method and use thereof

The invention discloses a quinazoline derivative shown in formula (I) which is described in the specification and a salt thereof. In the formula, Z represents -NH- and -O-, R1 and R2 represent C1-3 alkoxy groups or hydrogen, R3 is selected from the group consisting of 4-fluoro-, 4-chloro-, 2-chloro-, 4-bromo-, 2, 4-dichloro-, 4-methyl, 4-methoxy, hydrogen, 4-trifluoromethyl and 2,4-dimethoxy. The invention relates to a preparation method and application of the compound shown in the formula (I) and the salt thereof. The compound or the salt thereof has strong inhibitory activity on colorectal cancer cell strains HCT-116, human lung cancer cell strains A549 and breast cancer cell strains MCF-7. The compound has wide spectrum antitumor activity and can be used as a drug or lead compound for treatment of diseases like tumors and cancers.

Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus

In this study we report the synthesis, characterization, biological evaluation, and druglikeness assessment of a series of 20 novel isoxazolyl-sulfonamides, obtained by a four-step synthetic route. The compounds had their activity against Trypanosoma cruz

Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents

Secretory phospholipase A2 (sPLA2) is an important enzyme that plays a key role in various inflammatory diseases including cancer and its inhibitors have been developed as preventive or therapeutic agents. In the present study, a series of new indole containing isoxazole derivatives (10a–10o) is synthesized and evaluated for their sPLA2 inhibitory activities. All compounds (10a–10o) showed significant sPLA2 inhibition activities both in vitro and in vivo studies which is substantiated in in silico studies. Among all the tested compounds, 10o showed potent sPLA2 inhibition activity, that is comparable or more to ursolic acid (positive control). Further studies demonstrated that 10o showed in vitro antiproliferative activity when tested against MCF-7 breast and DU145 prostate cancer cells. Furthermore, compounds 10a–10o obeyed lipinsky's rule of 5 and suggesting druggable properties. The in vitro, in vivo and in silico results are encouraging and warrant pre-clinical studies to develop sPLA2-inhibitory compound 10o as novel therapeutic agent for various inflammatory disorders and several malignancies.